通过结合基于抗体的免疫疗法和小分子抑制剂来准急性白血病,进一步迈出了一步
Armin Dozandeh-Jouybari1,2, Erfan Rohaninia3, Sara Faaliat3
1Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Cancer cell international
|July 7, 2025
概括
使用基于抗体的治疗方法和小分子抑制剂的组合疗法在治疗急性白血病方面表现有前途,在临床试验中可能比单一疗法更有效.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 急性白血病,包括急性淋巴细胞白血病 (ALL) 和急性髓性白血病 (AML),是一种快速进展的骨髓疾病.
- 治疗急性白血病的常规化疗具有显著的副作用.
- 近几十年来,有针对性疗法的发展,重点关注白血病细胞特异性分子.
研究的目的:
- 审查针对急性白血病的基于抗体的向治疗方法.
- 讨论小分子抑制剂 (SMIs) 针对急性白血病中的细胞内分子.
- 评估将抗体介导疗法与SMI结合的潜力.
主要方法:
- 基于抗体的疗法的审查:免疫检查点抑制剂 (ICI),单克隆抗体和双特异性T细胞参与剂 (BiTEs).
- 小分子抑制剂 (SMIs) 针对激酶,BCL-2和SMO的讨论.
- 评估涉及抗体疗法和SMI的组合策略.
主要成果:
- 基于抗体的治疗方法改善了急性白血病的结果.
- 小微生物对特定的遗传变异和关键细胞分子有效.
- 组合疗法显示出协同作用的潜力.
结论:
- 结合抗体介导疗法和SMI可能与急性白血病单一治疗相比提供更高的疗效.
- 这种组合代表了急性白血病治疗的重大进步.
- 临床试验结果支持组合治疗的潜力.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.3K
06:51Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
15.3K
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
665
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
665
Hybridoma Technology
15.4K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.4K
